1. Company details

Name of entity: Virtus Health Limited ABN: 80 129 643 492

Reporting period: For the half-year ended 31 December 2014 Previous period: For the half-year ended 31 December 2013

2. Results for announcement to the market

The Directors of Virtus Health Limited ('Virtus') announce the results for the half-year ended 31 December 2014 ('H1 FY2015'). Key highlights from the results are:

			\$'000
Revenues from ordinary activities	up	12.9% to	114,488
Segment Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA)	up	6.2% to	37,954
Earnings Before Interest and Tax (EBIT)	up	1.4% to	28,264
Profit from ordinary activities after tax attributable to the owners of Virtus Health Limited	down	1.5% to	16,695
Profit from ordinary activities after tax	up	1.4% to	17,181
Profit for the half-year attributable to the owners of Virtus Health Limited	down	1.5% to	16,695
Dividends			Frankal
		Amount per security Cents	Franked amount per security Cents
Final ordinary dividend for the year ended 30 June 2014 paid in October 2	2014	14.000	14.000

An-interim dividend of 13.0 cents per share fully franked will be paid on 15 April 2015 to shareholders on the register at 3 April 2015.

Comments

The profit for the consolidated entity after providing for income tax and non-controlling interest amounted to \$16,695,000 (31 December 2013: \$16,941,000).

A reconciliation of Segment EBITDA to statutory profit before tax for the financial half-year is as follows:

	Consolidated		
	31 Dec 2014 \$'000	31 Dec 2013 \$'000	
Segment EBITDA	37,954	35,753	
Share-based payment expense	(410)	(302)	
Net gain on acquisition of associate	300	· -	
Corporate and other non-trading expenses	(9,580)	(7,575)	
EBIT	28,264	27,876	
Interest revenue	150	161	
Interest expense	(3,933)	(3,797)	
Amortisation of bank facility fees	(799)	(246)	
Profit before income tax from continuing activities	23,682	23,994	

Key features of the results are:

- Revenue increased by 12.9% to \$114.5m;
- EBITDA increased by 2.6% to \$32.8m;
- Australian segment EBITDA increased by 2.2% to \$36.8m;
- International segment EBITDA was \$1.2m after charging Singapore operation and business development costs (including commissioning expenses) of \$1,086,000;
- Segment EBITDA increased by 6.2% to \$38.0m; and
- Profit before income tax expense decreased to \$23.7m from \$24.0m.

Profit before tax includes commissioning and set-up costs in Singapore of \$911,000, acquisition transaction costs of \$857,000, a charge of \$653,000 reflecting the unamortised bank facility fees for the retired facility and a gain of \$300,000 on the remeasurement of the investment in IVF Sunshine Coast. Net profit before income tax expense adjusted for these items would have been \$25.8m, an increase of 7.5% against the prior year comparison.

Operating overview

Australia

There was a market volume contraction in New South Wales, Queensland and Victoria of 0.9% for Assisted Reproductive Services ("ARS") in the first half and the eastern state market outlook remains subdued.

Cycle growth in Virtus clinics in the first half has been neutral with growth in New South Wales and Victoria offset by continued weakness in the Queensland market. Virtus continue to experience growth in its "The Fertility Centre" branded clinics with all states meeting growth objectives however this growth has been offset by weakness in full service cycles.

Overall Virtus market share in the twelve months to December 2014 has increased to 45.6% from 45.0% for the equivalent twelve months to December 2013 and Virtus achieved like for like revenue growth of 1.6% in the period.

IVFA Australia opened a new ARS consulting and monitoring facility in Wahroonga, New South Wales in partnership with the Sydney Adventist Hospital.

Specialist diagnostic revenue increased by 17% in H1 FY2015, with greater utilisation of cytogenetic and non-invasive prenatal testing activities. Diagnostic test revenue growth continues to be a focus for the business and Virtus has invested in new gene sequencing equipment to further develop our capability and patient services in our PGD and genetic test activities.

In our day hospitals Virtus achieved revenue growth of 3.7% with good performances achieved at City West and City East in Sydney and East Melbourne where utilisation rates improved and process efficiencies were also implemented. Our joint venture, City West Specialist Day Hospital achieved a very strong result after adding non-IVF procedures from the public and private sectors; non-IVF procedure revenue increased by 8.7% across all day hospitals and now accounts for 56% of day hospital revenue.

International

Virtus completed the development and commissioning of a new Virtus branded clinic in Singapore. Operating costs of the business development operation activity in Singapore were \$1,086,000 in the period. Virtus has contracted three fertility specialists in Singapore and IVF cycles commenced during January 2015.

Sims Clinic, acquired in May 2014, enjoyed a strong first half with volumes increasing by 25% compared to H1 FY2014; EBITDA margin improved to 24% of revenue. Sims Clinic also completed the development and commissioning of a new full service IVF clinic in Cork.

Capital Expenditure

Total expenditure on tangible and intangible assets was \$6.3m in H1 FY2015 (H1 FY2014; \$2.5M) including approximately \$3.0m in our new facility in Singapore.

Acquisitions

Virtus has completed three acquisitions since 30 June 2014:

- IVF Sunshine Coast since acquiring the remaining 80% of this full service clinic at the end of October, in conjunction with the three fertility specialists and the Scientific Director Virtus has established two new clinics:
 - o IVF Sunshine Coast, a full service clinic based in Buderim; and
 - o a new TFC, based at Kawana Private Hospital
- •Tas IVF Virtus acquired 70% of Tasmania's leading IVF clinic based in Hobart on 5 December; and
- Human Assisted Reproductions Limited, ("Rotunda IVF"); our 70% owned subsidiary, Sims Clinic acquired an Irish fertility centre, the HARI clinic from the Rotunda Hospital in Dublin for €6 million on 31 December 2014; Rotunda IVF has three full time fertility specialists.

Debt and interest expense

Virtus negotiated a new Syndicate Facility Agreement with the existing group of facility providers and this was completed in October 2014. The total facility available was increased by \$60m to \$210m and the consolidated entity comfortably met the financial covenants as set out in the agreement.

At 31 December 2014, total facilities drawn were \$148m in cash and \$3,376,000 in guarantees. Cash balances at the end of December 2014 were \$9,663,000.

Amortisation of borrowing costs

Amortisation of borrowing cost expense for H1 FY2015 was \$0.8m, including a write off of \$0.7m in respect of the now retired Syndicate Facility Agreement originally established at the IPO in June 2013.

Taxation

The effective tax rate on operating earnings for H1 FY2015 was 27.5% (H1 FY2014; 29.4%) as a consequence of the true-up of the prior and current year R&D tax concession and also the lower tax rate applied to the Virtus Ireland activities.

Earnings per share

Basic earnings per share decreased by 1.7% to 20.93 cents per share (December 2013: 21.30 cents per share). Diluted earnings per share decreased by 2.4% to 20.71 cents per share (December 2013: 21.24 cents per share).

Dividend

Ne

An interim dividend of 13.00 cents per share fully franked (April 2014: 12.00 cents per share) will be paid on 15 April to shareholders on the register at 3 April.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
et tangible assets per ordinary security	(182.50)	(111.07)

4. Control gained over entities

Name of entities (or group of entities)

IVF Sunshine Coast Limited, TAS IVF Pty Limited and Human Assisted

Reproduction Ireland (HARI) Limited

Date control gained

31 October 2014, 5 December 2014 and 31 December 2014

\$'000

Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities before income tax during the period (where material)

257

Profit/(loss) from ordinary activities before income tax of the controlled entity (or group of entities) for the whole of the previous period (where material)

N/A

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

	Franked
Amount per	amount per
security	security
Cents	Cents

Final ordinary dividend for the year ended 30 June 2014 paid in October 2014

14.000

14.000

An interim dividend of 13.0 cents per share fully franked will be paid on 15 April 2015 to shareholders on the register at 3 April 2015.

Previous period

	Franked
Amount per	amount per
security	security
Cents	Cents

Interim ordinary dividend for the half year ended 31 December 2013 paid in April 2014

12.000

12.000

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

	Reporting entity's percentage holding		Contribution to profit/(loss) (where material)	
Name of associate / joint venture	Reporting period %	Previous period %	Reporting period \$'000	Previous period \$'000
Obstetrics & Gynaecological Imaging Australia Pty Limited and City West Specialist Day Hospital Pty Ltd	50.00%	50.00%	341	143
Group's aggregate share of associates and joint venture entities' profit/(loss) (where material) Profit/(loss) from ordinary activities before income tax			341	143
Income tax on operating activities			(102)	(43)

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

11. Attachments

Details of attachments (if any):

The Interim Report of Virtus Health Limited for the half-year ended 31 December 2014 is attached.

12. Signed

Signed

Glenn Powers Chief Financial Officer and Company Secretary

Sydney

Date: 24 February 2015

Virtus Health Limited

ABN 80 129 643 492

Interim Report - 31 December 2014

Virtus Health Limited Directors' report 31 December 2014

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Virtus Health Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2014.

Directors

The following persons were directors of Virtus Health Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Peter Macourt - Chairman

Susan Channon

Dennis O'Neill

Lyndon Hale

Peter Turner

Sonia Petering (appointed on 1 September 2014)

Marcus Darville (resigned on 7 October 2014)

Principal activities

During the financial half-year the principal continuing activities of the consolidated entity were the provision of healthcare services which include fertility services, medical day procedure services and medical diagnostic services.

Review of operations

The profit for the consolidated entity after providing for income tax and non-controlling interest amounted to \$16,695,000 (31 December 2013: \$16,941,000).

Profit before income tax expense decreased to \$23,682,000 from \$23,994,000, primarily a consequence of non-recurring charges relating to acquisition transaction costs (\$857,000) and amortisation of bank facility fees for the retired bank facility agreement (\$653,000).

Segment EBITDA is a financial measure which is not prescribed by Australian Accounting Standards ('AAS') and represents the profit under AAS adjusted for non-specific non-cash and significant items.

A reconciliation of Segment EBITDA to profit before tax for the financial half-year is as follows:

	Consolidated			
	31 Dec 2014 \$'000	31 Dec 2013 \$'000		
Segment EBITDA	37,954	35,753		
Share-based payment expense	(410)	(302)		
Net gain on acquisition of associate	300	· -		
Corporate and other non-trading expenses	(9,580)	(7,575)		
EBIT	28,264	27,876		
Interest revenue	150	161		
Interest expense	(3,933)	(3,797)		
Amortisation of bank facility fees	(799)	(246)		
Profit before income tax from continuing activities	23,682	23,994		

The consolidated entity continued to engage in its principal activities, the results of which are disclosed in the attached financial statements.

For further details refer to ASX market announcement on 24 February 2015.

1

Virtus Health Limited Directors' report 31 December 2014

Significant changes in the state of affairs

In September 2014 Virtus Health renegotiated and extended its bank facilities to September 2019 and added a further \$60 million debt capacity to support its growth and acquisition strategies.

Virtus Health acquired 80% of the issued share capital and units of IVF Sunshine Coast Pty Ltd on 31 October 2014; 70% of the issued share capital and units of Tas IVF Pty Ltd on 5 December 2014; and formed a new company, Human Assisted Reproduction Ireland on 31 December 2014 to acquire the IVF business and assets from The Governors and Guardians of the Hospital For The Relief Of Poor Lying In Women, Dublin (commonly known as the Rotunda Hospital). For more information please refer to note 12.

There were no other significant changes in the state of affairs of the consolidated entity during the financial half-year.

Rounding of amounts

The company is of a kind referred to in Class Order 98/100, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Class Order to the nearest thousand dollars, or in certain cases, the nearest dollar.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on the following page.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors

Peter Macourt Chairman

24 February 2015 Sydney



Auditor's Independence Declaration

As lead auditor for the review of Virtus Health Limited for the half-year ended 31 December 2014, I declare that to the best of my knowledge and belief, there have been:

- a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- b) no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Virtus Health Limited and the entities it controlled during the period.

Eddie Wilkie

Partner

PricewaterhouseCoopers

Eddoe Willie

Sydney 24 February 2015

Virtus Health Limited Contents 31 December 2014

Contents

Statement of comprehensive income	5
Statement of financial position	6
Statement of changes in equity	7
Statement of cash flows	8
Notes to the financial statements	9
Directors' declaration	19
independent auditor's review report to the members of Virtus Health Limited	20

General information

The financial statements cover Virtus Health Limited as a consolidated entity consisting of Virtus Health Limited and its subsidiaries. The financial statements are presented in Australian dollars, which is Virtus Health Limited's functional and presentation currency.

Virtus Health Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Level 3 176 Pacific Highway Greenwich NSW 2065

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 24 February 2015. The directors have the power to amend and reissue the financial statements.

Virtus Health Limited Statement of comprehensive income For the half-year ended 31 December 2014

	Note	Consol 31 Dec 2014 \$'000	
Revenue	3	114,488	101,415
Share of profits of associates accounted for using the equity method Other income	4	341 597	143 127
Expenses Fertility specialists, consumables and associated costs Employee benefits expense Depreciation and amortisation expense Occupancy expense Advertising and marketing Practice equipment expenses Professional and consulting fees Other expenses Finance costs Profit before income tax expense Income tax expense	5	(30,259) (35,990) (4,541) (6,671) (1,452) (852) (2,054) (5,193) (4,732) 23,682	(26,850) (30,213) (4,104) (5,724) (1,236) (614) (759) (4,148) (4,043) 23,994 (7,053)
Profit after income tax expense for the half-year		17,181	16,941
Other comprehensive income Items that may be reclassified subsequently to profit or loss Net change in the fair value of cash flow hedges taken to equity, net of tax Foreign currency translation		(369) 951	118 <u>3</u>
Other comprehensive income for the half-year, net of tax		582	121
Total comprehensive income for the half-year		17,763	17,062
Profit for the half-year is attributable to: Non-controlling interest Owners of Virtus Health Limited		486 16,695 17,181	16,941 16,941
Total comprehensive income for the half-year is attributable to: Non-controlling interest Owners of Virtus Health Limited		797 16,966 17,763	17,062 17,062
		Cents	Cents
Basic earnings per share Diluted earnings per share	14 14	20.93 20.71	21.30 21.24

	Consolie		idated
	Note	31 Dec 2014 \$'000	30 Jun 2014 \$'000
Assets			
Current assets			
Cash and cash equivalents		9,663	21,498
Trade and other receivables		11,125	12,478
Inventories		362	166
Other		1,963	1,371
Total current assets		23,113	35,513
Non-current assets			
Investments accounted for using the equity method		1,489	1,489
Property, plant and equipment		30,510	28,207
Intangibles		391,439	356,077
Deferred tax		8,395	8,154
Other		308	341
Total non-current assets		432,141	394,268
Total assets		455,254	429,781
Liabilities			
Current liabilities			
Trade and other payables		21,565	23,516
Borrowings		48	62
Income tax		4,991	4,507
Provisions		2,871	2,418
Other		4,002	3,634
Total current liabilities		33,477	34,137
Non-current liabilities			
Borrowings		147,173	139,416
Derivative financial instruments		665	137
Provisions		5,136	4,663
Other financial liability	6	23,157	11,802
Total non-current liabilities		176,131	156,018
Total liabilities		209,608	190,155
Net assets		245,646	239,626
Equity			
Issued capital	7	238,145	237,135
Reserves	8	(11,781)	•
Accumulated losses		(482)	(6,139)
Equity attributable to the owners of Virtus Health Limited		225,882	229,386
Non-controlling interest		19,764	10,240
Total equity		245,646	239,626

Virtus Health Limited Statement of changes in equity For the half-year ended 31 December 2014

Consolidated	Issued capital \$'000	Reserves \$'000	Accumulated losses \$'000	Non- controlling interest \$'000	Total equity \$'000
Balance at 1 July 2013	231,981	10,186	(27,578)	-	214,589
Profit after income tax expense for the half- year Other comprehensive income for the half-year, net of tax	-	- 121	16,941	-	16,941 121
Total comprehensive income for the half-year Transactions with owners in their capacity as	-	121	16,941	-	17,062
owners: Share-based payments Tax benefit now determined relating to a portion of option adjustment payments made in	-	302	-	-	302
June 2013	4,097	-			4,097
Balance at 31 December 2013	236,078	10,609	(10,637)		236,050
Consolidated	Issued capital \$'000	Reserves \$'000	Accumulated losses \$'000	Non- controlling interest \$'000	Total equity \$'000
Balance at 1 July 2014	237,135	(1,610)	(6,139)	10,240	239,626
Profit after income tax expense for the half- year Other comprehensive income for the half-year,	-	-	16,695	486	17,181
net of tax Total comprehensive income for the half-year		<u>271</u> 271	16,695	311 797	582 17,763
Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs (note 7) Share-based payments	1,010	- 410	- -	- -	1,010 410
Put option business combination reserve Non-controlling interest on acquisition of subsidiary	-	(10,852)	-	6,940	(10,852) 6,940
Issue of shares - non controlling interest Dividends paid (note 9)	<u> </u>		(11,038)	1,787 	1,787 (11,038)
Balance at 31 December 2014	238,145	(11,781)	(482)	19,764	245,646

Virtus Health Limited Statement of cash flows For the half-year ended 31 December 2014

	Consolidated 31 Dec 2014 31 De \$'000 \$'0	
Cash flows from operating activities		
Receipts from customers (inclusive of GST)	115,681	99,778
Payments to suppliers (inclusive of GST)	(85,303)	(71,527)
Other revenue	297	145
Interest and other finance costs paid	(3,502)	(3,432)
Income taxes paid	(5,627)	(2,754)
Net cash from operating activities	21,546	22,210
Cash flows from investing activities		
Payments for acquisition of subsidiary and businesses, net of cash acquired	(25,692)	<u>-</u>
Payments for property, plant and equipment and intangibles	(6,310)	(2,497)
Proceeds from sale of property, plant and equipment	27	-
Interest received	150	161
Associate distributions received		143
New years would be investigated and the state of the stat	(24.005)	(0.400)
Net cash used in investing activities	(31,825)	(2,193)
Cook flavor from financing activities		
Cash flows from financing activities Proceeds from issue of shares and other equity securities	710	
Proceeds from issue of shares and other equity securities - non-controlling interest	1,787	-
Payment of dividends	(11,038)	-
Proceeds from borrowings	8,000	-
Repayment of borrowings	0,000	(13,000)
Payment of borrowings Payment of finance facility fees in relation to refinancing	(1,038)	(13,000)
Payment for finance lease facility	(26)	(107)
1 ayment for illiance lease racility	(20)	(107)
Net cash used in financing activities	(1,605)	(13,107)
110t odoli doca ili ililancing dolividos	(1,000)	(10,101)
Net increase/(decrease) in cash and cash equivalents	(11,884)	6,910
Cash and cash equivalents at the beginning of the financial half-year	21,498	12,485
Effects of exchange rate changes on cash and cash equivalents	49	, . 33
9 1111 311 111 1 1		
Cash and cash equivalents at the end of the financial half-year	9,663	19,395
	-,-35	-,

Note 1. Significant accounting policies

These general purpose financial statements for the interim half-year reporting period ended 31 December 2014 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2014 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New, revised or amending Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity during the financial half-year ended 31 December 2014 and are not expected to have any significant impact for the full financial year ending 30 June 2015. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Comparatives

Comparatives in the statement of comprehensive income have been reclassified, where necessary, to align with the current period presentation. There was no effect on profit or net assets.

Note 2. Operating segments

Identification of reportable operating segments

AASB 8 'Operating Segments' requires operating segments to be identified on the basis of internal reports about components of the consolidated entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance. For disclosure purposes the consolidated entity currently has two operating segments being Australia and International. The consolidated entity has determined that a disclosure of segments, healthcare services, Australia and International respectively is most appropriate due to the economic characteristics faced by the operating segments and the similar nature of the products and services being delivered to a similar patient base.

Segment revenue

Sales between segments are carried out at arm's length and are eliminated on consolidation. The revenue from external parties reported to the Board of Directors is measured in a manner consistent with that in the statement of comprehensive income.

Segment EBITDA

Segment performance is assessed on the basis of Segment EBITDA. Segment EBITDA comprises expenses which are incurred in the normal trading activity of the segments and excludes the impact of depreciation, amortisation, interest, share-based payments and other items which are determined to be outside of the control of the respective segments.

Revenue from external customers is derived from the provision of healthcare services. A breakdown of revenue and results is provided below:

Note 2. Operating segments (continued)

Operating segment information

Consolidated - 31 Dec 2014	Healthcare services Australia \$'000	Healthcare services International \$'000	Intersegment eliminations/ unallocated \$'000	Total \$'000
Revenue Sales to external customers Intersegment sales	103,419 1,229	10,449	(1,229)	113,868
Total sales revenue Other revenue Interest revenue	104,648 470 133	10,449	(1,229) - - - - - - - - - - - - - - - - - - -	113,868 470 150
Total revenue Segment EBITDA Share based payment expanse	105,251 36,765	10,450	(1,213)	37,954 (410)
Share-based payment expense Transaction costs Net gain on acquisition of associate Corporate costs Depreciation and amortisation expenses Interest revenue Interest expense				(410) (857) 300 (4,182) (4,541) 150 (3,933)
Amortisation of bank facility fees Profit before income tax expense Income tax expense Profit after income tax expense			- - -	(799) 23,682 (6,501) 17,181
Assets Segment assets Unallocated assets:	501,035	48,626	(107,816)	441,845
Cash and cash equivalents Property, plant and equipment Deferred tax asset Other receivables Intangibles			_	1,703 1,169 8,395 549 1,593
Total assets Liabilities			_	455,254
Segment liabilities Unallocated liabilities: Provision for income tax	129,043	33,220	(115,107)	47,156 4,992
Trade payables Other payables Employee provisions Non-current borrowings				393 978 729 147,015
Derivative financial instruments Other financial liabilities Total liabilities			- -	665 7,680 209,608

Note 2. Operating segments (continued)

Consolidated - 31 Dec 2013	Healthcare services Australia \$'000	Healthcare services International \$'000	Intersegment eliminations/ unallocated \$'000	Total \$'000
Revenue				
Sales to external customers	100,850	-	-	100,850
Intersegment sales	2,303	-	(2,303)	· -
Total sales revenue	103,153	-	(2,303)	100,850
Other revenue	404	-	-	404
Interest revenue	161			161
Total revenue	103,718		(2,303)	101,415
Segment EBITDA	35,991	(238)	-	35,753
Share-based payment expense				(302)
Fransaction costs				(43)
Depreciation and amortisation expenses				(4,104)
Corporate costs				(3,428)
Interest revenue				161
Interest expense				(3,797)
Amortisation of bank facility fees			=	(246)
Profit before income tax expense Income tax expense				23,994 (7,053)
Profit after income tax expense			=	16,941
Consolidated - 30 Jun 2014 Assets				
Segment assets	484,651	39,461	(111,685)	412,427
Unallocated assets:			(111,000)	712,721
Cash and cash equivalents				5,857
Deferred tax asset				8,140
Other receivables				1,150
Property, plant and equipment				1,098
Intangibles			=	1,109
Total assets			_	429,781
Liabilities				
Segment liabilities	132,925	17,006	(106,579)	43,352
Unallocated liabilities:	<u> </u>			
Trade payables				1,239
Other payables				1,047
Provision for income tax				4,507
Employee provisions				620
Non-current borrowings				139,253
Derivative financial instruments			_	137
Total liabilities			_	190,155

Note 3. Revenue

	Consol 31 Dec 2014 \$'000	
Sales revenue Rendering of services	113,868	100,850
Other revenue	450	404
Interest Rent	150 470	161 404
Reill	620	565
Revenue	114,488	101,415
		
Note 4. Other income		
	Consol 31 Dec 2014 \$'000	
Net gain on acquisition of associate Other income	300 297	- 127
Other income	597	127
Note 5. Expenses		
	Consol 31 Dec 2014	
Profit before income tax includes the following specific expenses:	\$'000	\$ 000
Finance costs Interest and finance charges paid/payable	3,933	3,797
Amortisation of bank facility fees	799	246
Finance costs expensed	4,732	4,043
Share-based payments expense Share-based payments expense - fertility specialists	163	142
Share-based payments expense - employee benefits	247	160
	410	302
Total share-based payments expense		
Total share-based payments expense Note 6. Non-current liabilities - other financial liability		
	Consol 31 Dec 2014 \$'000	lidated 30 Jun 2014 \$'000

The other financial liability represents the fair value of the put options held by the non-controlling interests in Sims Clinic Limited, TAS IVF Pty Limited and Human Assisted Reproduction Ireland (HARI) Limited.

Note 7. Equity - issued capital

		Consolidated			
		31 Dec 2014 Shares	30 Jun 2014 Shares	31 Dec 2014 \$'000	30 Jun 2014 \$'000
Ordinary shares - fully paid		79,885,938	79,722,678	238,145	237,135
Movements in ordinary share capital					
Details	Date		No of shares	Issue price	\$'000
Balance Shares issued - exercise of options Shares issued - acquisition of IVF Sunshine Coast	1 July 20 18 Septe 31 Octob	mber 2014	79,722,678 125,000	\$5.68	237,135 710
Pty Limited	31 Octor	DEI 2014	38,260	\$7.84	300
Balance	31 Decei	mber 2014	79,885,938		238,145
Note 8. Equity - reserves					
				Conso	
				31 Dec 2014 \$'000	30 Jun 2014 \$'000
Foreign currency reserve Hedging reserve - cash flow hedges Share-based payments reserve Put option business combination reserve				240 (465) 11,052 (22,608)	(400) (96) 10,642 (11,756)
				(11,781)	(1,610)
Note 9. Equity - dividends					
Dividends paid during the financial half-year were as	follows:				
				Conso	
\bigcirc				31 Dec 2014 \$'000	31 Dec 2013 \$'000
Final dividend of 14.0 cents per fully paid share paid	in October	2014		11,038	-

An interim dividend of 13.0 cents per share fully franked will be paid on 15 April 2015 to shareholders on the register at 3 April 2015.

Note 10. Fair value measurement

Fair value hierarchy

The following tables detail the consolidated entity's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: Unobservable inputs for the asset or liability

Consolidated - 31 Dec 2014	Level 1 \$'000	Level 2 \$'000	Level 3 \$'000	Total \$'000
Liabilities				
Derivative financial liabilities	-	665	-	665
Other financial liability			23,157	23,157
Total liabilities		665	23,157	23,822
Consolidated - 30 Jun 2014	Level 1 \$'000	Level 2 \$'000	Level 3 \$'000	Total \$'000
Liabilities				
Derivative financial liabilities	_	137	_	137
Other financial liability	-	-	11,802	11,802
Total liabilities		137	11,802	11,939

Level 3 assets and liabilities

Movements in level 3 assets and liabilities during the current financial half-year are set out below:

Consolidated	Other financial liabilities \$'000	Total \$'000
Balance at 1 July 2014 Additions	11,802 11,355	11,802 11,355
Balance at 31 December 2014	23,157	23,157

Note 11. Contingent liabilities

Claims

The consolidated entity is currently involved in litigations which may result in future liabilities and legal fees up to an insurance excess of \$25,000 (30 June 2014: \$25,000). The consolidated entity has disclaimed liability and is defending the actions. It is not practical to estimate the potential effect of these claims but advice indicates that any liability that may arise in the unlikely event that the claims are successful will not be significant and will be covered by the consolidated entity's insurance policies.

Guarantees

Drawdowns of \$3,375,912 (30 June 2014: \$3,998,000) in the form of financial guarantees have been made against the working capital facility.

Note 12. Business combinations

IVF Sunshine Coast Limited

On 31 October 2014 Queensland Fertility Group Pty Limited, a fully owned subsidiary of Virtus Health Limited, acquired the remaining 80% of the issued share capital and units of IVF Sunshine Coast Pty Limited. Total consideration transferred amounted to \$1,302,000. The values identified in relation to the acquisition of the businesses are provisional as at 31 December 2014.

Details of the acquisition are as follows:

		Fair value \$'000
Cash and cash equivalents		135
Trade receivables and other receivables Income tax refund due		33 22
Other current assets		31
Plant and equipment		183 45
Deferred tax asset Trade payables and other		(54)
Lease make good provision		(12)
Other provisions Deferred revenue		(133) (182)
Lease liability		(173)
Net liabilities acquired		(105)
Goodwill		1,407
Acquisition-date fair value of the total consideration transferred		1,302
Representing: Cash paid or payable to vendor		750
Virtus Health Limited shares issued to vendor		300
Gain on remeasurement of previously held 20% investment to fair value		300
Working capital movement - amount not yet paid		(48)
		1,302
Acquisition costs expensed to profit or loss	:	108
	Consol	idated
	31 Dec 2014 \$'000	31 Dec 2013 \$'000
Cash used to acquire business, net of cash acquired:		
Acquisition-date fair value of the total consideration transferred	1,002	-
Less: cash and cash equivalents Less: shares issued by company as part of consideration	(135) (300)	-
Working capital adjustment	48	<u> </u>
Net cash used	615	-

The acquired business contributed revenues and other income of \$356,044 and profit before tax of \$95,403 (excluding the cost of financing the transaction) to the consolidated entity for the period from 1 November 2014 to 31 December 2014. If the acquisition had occurred on 1 July 2014, the full half-year contributions would have been revenues of \$877,546 and loss before tax of \$10,449 excluding any additional financing or brand amortisation costs. These amounts have been calculated using the consolidated entity's accounting policies and by adjusting the results of the subsidiary to reflect the additional depreciation and amortisation that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had applied from 1 July 2014, together with the consequential tax effects.

Note 12. Business combinations (continued)

Tas IVF Pty Ltd

On 5 December 2014 Virtus Health Limited, acquired 70% of the issued share capital and units of Tas IVF Pty Ltd. Total consideration transferred amounted to \$16,676,000. The values identified in relation to the acquisition of the businesses are provisional as at 31 December 2014.

Details of the acquisition are as follows:

		Fair value \$'000
Cash and cash equivalents Trade receivables and other Plant and equipment Brands		5,756 439 488 886
Other intangible assets Deferred tax asset Trade and other payables Provision for income tax		7 10 (310) (388)
Employee benefits Short-term debt Deferred revenue		(343) (5,309) (285)
Net assets acquired Goodwill		951 22,665
Acquisition-date fair value of the total consideration transferred		23,616
Representing: Cash paid or payable to vendor Working capital movement Non-controlling interest		16,100 576 6,940
		23,616
Acquisition costs expensed to profit or loss	:	227
	Consol 31 Dec 2014 \$'000	
Cash used to acquire business, net of cash acquired: Acquisition-date fair value of the total consideration transferred Less: cash and cash equivalents Add: short-term debt Working capital adjustment - amount not yet paid	16,676 (5,756) 5,309 (576)	- - - -
Net cash used	15,653	_

The acquired business contributed revenues and other income of \$657,631 and profit before tax of \$230,306 (excluding the cost of financing the transaction) to the consolidated entity for the period from 1 December 2014 to 31 December 2014. If the acquisition had occurred on 1 July 2014, the full half-year contributions would have been revenues of \$4,187,588 and profit before tax of \$1,687,555 excluding any additional financing costs. These amounts have been calculated using the consolidated entity's accounting policies and by adjusting the results of the subsidiary to reflect the additional depreciation and amortisation that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had applied from 1 July 2014, together with the consequential tax effects.

Note 12. Business combinations (continued)

Human Assisted Reproduction Ireland (HARI) Limited

On 31 December 2014 Sims Clinic Limited (a 70% subsidiary of Virtus Health Limited), formed a new company, Human Assisted Reproduction Ireland (HARI) Limited to acquire the IVF business and assets from The Governors and Guardians of the Hospital For The Relief Of Poor Lying In Women, Dublin (commonly known as the Rotunda Hospital). Total consideration transferred amounted to \$9,041,000. The values identified in relation to the acquisition of the businesses are provisional as at 31 December 2014.

Details of the acquisition are as follows:

	Fair value \$'000
Trade receivables and other receivables Plant and equipment Employee benefits Deferred revenue	184 259 (45) (549)
Net liabilities acquired Goodwill	(151) 9,192
Acquisition-date fair value of the total consideration transferred	9,041
Representing: Cash paid or payable to vendor	9,041
Acquisition costs expensed to profit or loss	522
	Consolidated 31 Dec 2014 31 Dec 2013 \$'000 \$'000
Cash used to acquire business, net of cash acquired: Acquisition-date fair value of the total consideration transferred	9,041

As Virtus only acquired the business and assets of the Rotunda Hospital and formed a new company on 31 December 2014, there is no effect to the current half-year's revenues and other income or profit before tax. If the acquisition had occurred on 1 July 2014, the full half-year contributions would have been revenues of \$3,424,000 and profit before tax of \$819,500 excluding any additional financing costs. These amounts have been calculated using the consolidated entity's accounting policies and by adjusting the results of the subsidiary to reflect the additional depreciation and amortisation that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had applied from 1 July 2014, together with the consequential tax effects.

Note 13. Events after the reporting period

Apart from the dividend declared as disclosed in note 9, no other matter or circumstance has arisen since 31 December 2014 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 14. Earnings per share

	Consolidated	
	31 Dec 2014 \$'000	31 Dec 2013 \$'000
Profit after income tax Non-controlling interest	17,181 (486)	16,941
Profit after income tax attributable to the owners of Virtus Health Limited Add: interest savings on conversion of options	16,695 63	16,941 191
Profit after income tax attributable to the owners of Virtus Health Limited used in calculating diluted earnings per share	16,758	17,132
<u>as</u>	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share Adjustments for calculation of diluted earnings per share:	79,758,294	79,536,601
Options over ordinary shares	1,139,660	1,111,111
Weighted average number of ordinary shares used in calculating diluted earnings per share	80,897,954	80,647,712
	Cents	Cents
Basic earnings per share Diluted earnings per share	20.93 20.71	21.30 21.24

Virtus Health Limited Directors' declaration 31 December 2014

In the directors' opinion:

- the attached financial statements and notes thereto comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes thereto give a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors

Peter Macourt Chairman

24 February 2015 Sydney



Independent auditor's review report to the members of Virtus Health Limited

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Virtus Health Limited (the Company), which comprises the statement of financial position as at 31 December 2014, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, selected explanatory notes and the directors' declaration for the Virtus Health Limited Group (the consolidated entity). The consolidated entity comprises the company and the entities it controlled from time to time during the half-year.

Directors' responsibility for the half-year financial report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including the Australian Accounting Interpretations) and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Australian Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of Virtus Health Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.



Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Virtus Health Limited is not in accordance with the Corporations Act 2001 including:

- a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the half-year ended on that date;
- b) complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

Pricewaterhouse Coopers Eddre Wilhie

Eddie Wilkie

Partner

Sydney 24 February 2015